Abstract:Abstract Abstract 2846 Poster Board II-822 Background: A prominent feature of most cancers is striking genetic instability and ongoing accrual of mutational changes associated with tumor progression, including acquisition of invasiveness, drug resistance, and metastasis. Methods: We first utilized single nucleotide polymorphism (SNP) arrays (Affymetrix) to evaluate genome-wide gains and losses in copy number and heterozygosity in CD138+ multiple myeloma (MM) cells collected from 14 patients at two time points at least 6 months apart. To estimate the extent of genomic instability in each patient, the number of events leading to copy number or heterozygosity changes throughout the genome were calculated. An event was defined as detectable change in copy number or heterozygosity in three or more consecutive SNPs. Two cases were also investigated for genome-wide rearrangements utilizing a paired-end approach on next generation sequencing. Results: In a period of six months, all MM patients analyzed acquired multiple new mutational events including changes in copy number and heterozygosity, ranging from 0.021 - 2.674 %, indicating a wide range of genetic instability. Although the rate of mutation varied, the majority (71%) of MM patients had acquired > 100 mutational events within the six months period, thus indicating a striking genetic instability. Chromosomes 1, 13, and X were unique with respect to copy number changes and showed large areas of change, spanning the entire length of a chromosome in several patient samples analyzed. Chromosomes 1 and 13 also showed large areas of loss or gain of heterozygosity in several patients, indicating areas of recurrent changes. We were also able to correlate genomic changes with changes in expression of corresponding genes. In two cases, we investigated genome-wide rearrangements utilizing a massively parallel sequencing approach. Short insert (400bp) libraries from two samples collected 6 months apart were constructed and subjected to paired-end sequencing utilizing 37bp readlengths on the Illumina GAII instrument. Approximately 80 million reads were generated for each of the 4 samples. Read pairs were mapped back to the reference genome, and those mapping aberrantly (incorrect orientation, different chromosomes, incorrect genomic distance) were further analyzed. Bespoke PCR assays defining each breakpoint were designed and used to verify the somatic nature of the mapped rearrangement. Further, PCR fragments spanning somatic genomic rearrangements were sequenced to generate base-pair resolution of breakpoints. To date, 29 somatic rearrangements have been sequenced, including three that were present only in the second sample. One of these was on chromosome 13. Breakpoint sequencing revealed a 64.9Kb homozygous (no wild-type readpairs found) deletion removing the first two exons of the RB1 gene. No reads spanning this breakpoint were found in the matching sample taken six months earlier. Conclusions: This is the first study utilizing massively parallel sequencing to investigate the MM genome and provides important insight into the pathogenesis of disease progression .as well as confirms the potential of whole genome sequencing to inform biology of the disease that may affect the therapeutic approach in future. Disclosures: Munshi: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis : Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Richardson:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millennium Pharmaceuticals, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Anderson:Celgene: Consultancy, Honoraria, Research Funding; Millennium: Consultancy, Honoraria, Research Funding; Novartis : Consultancy, Honoraria, Research Funding.

MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution

Tumor Diversity and Evolution Revealed Through RADseq

Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

Pharming: Joint Clonal Tree Reconstruction of SNV and CNA Evolution from Single-cell DNA Sequencing of Tumors

Chromosome evolution screens recapitulate tissue-specific tumor aneuploidy patterns

Single-cell copy number calling and event history reconstruction

Abstract PR012: Evolutionary dynamics of whole-genome doubling in ovarian cancer

Abstract 4338: A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution

Cancer phylogenetic tree inference at scale from 1000s of single cell genomes

Differential whole-genome doubling and homologous recombination deficiencies across breast cancer subtypes from the Taiwanese population

SCONCE: a method for profiling copy number alterations in cancer evolution using single-cell whole genome sequencing

Abstract 7419: Seq2Karyotype (S2K): A method for deconvoluting heterogeneity of copy number alterations using single-sample whole-genome sequencing data

Copy Number Analysis Of Whole-Genome Data Using Bic-Seq2 And Its Application To Detection Of Cancer Susceptibility Variants

SiCloneFit: Bayesian inference of population structure, genotype, and phylogeny of tumor clones from single-cell genome sequencing data

CLImAT-HET: Detecting Subclonal Copy Number Alterations and Loss of Heterozygosity in Heterogeneous Tumor Samples from Whole-Genome Sequencing Data.

Inferring clonal evolution of tumors from single nucleotide somatic mutations

The History of Chromosomal Instability in Genome-Doubled Tumors

Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer

Abstract 1200: A novel algorithm for deconvolving cancer allele-specific clone copy number and copy number evolution

NestedBD: Bayesian inference of phylogenetic trees from single-cell copy number profiles under a birth-death model

Whole Genome Paired End Sequencing Identifies Genomic Evolution In Myeloma.